Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

Clinical lung cancer - 1 Nov 2014

Chaft Jamie E, Litvak Anya, Arcila Maria E, Patel Payal, D'Angelo Sandra P, Krug Lee M, Rusch Valerie, Mattson Alicia, Coeshott Claire, Park Bernard, Apelian David M, Kris Mark G, Azzoli Christopher G

Abstract excerpt

INTRODUCTION: Patients with early-stage lung cancer have a high risk of recurrence despite multimodality therapy. KRAS-mutant lung adenocarcinomas are the largest genetically defined subgroup, representing 25% of patients. GI-4000 is a heat-killed recombinant Saccharomyces cerevisiae yeast-derived vaccine expressing mutant KRAS proteins. The present phase II study assessed the feasibility, immunogenicity, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP-Binding Protein alpha Subunits, G12-G13

Share to Lymphocyte Activation

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to T-Lymphocytes

Source

Identifiers

PMID: 25044103
DOI: 10.1016/j.cllc.2014.06.002

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.PMID 25044103Read ↗

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read ↗

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study.Semantic proximity Read ↗

Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersSemantic proximity Read ↗

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine.Semantic proximity Read ↗

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.Semantic proximity Read ↗

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.Semantic proximity Read ↗

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.Semantic proximity Read ↗

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapySemantic proximity Read ↗

KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.Semantic proximity Read ↗

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.Semantic proximity Read ↗

A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.Semantic proximity Read ↗

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.